A5062689531- Heart Failure Treatment and Management
- Nitric Oxide and Endothelin Effects
- Pulmonary Hypertension Research and Treatments
- Neuroscience and Music Perception
- Reading and Literacy Development
- Intracranial Aneurysms: Treatment and Complications
- Traumatic Brain Injury and Neurovascular Disturbances
- Lysosomal Storage Disorders Research
- Cardiovascular Function and Risk Factors
- Neurosurgical Procedures and Complications
- Multisensory perception and integration
- Cognitive and developmental aspects of mathematical skills
- Neural and Behavioral Psychology Studies
- Music and Audio Processing
- Glycogen Storage Diseases and Myoclonus
- Cardiovascular and exercise physiology
- EEG and Brain-Computer Interfaces
- Systemic Sclerosis and Related Diseases
- Dermatologic Treatments and Research
- Neurobiology of Language and Bilingualism
- Parkinson's Disease Mechanisms and Treatments
- Categorization, perception, and language
- Vascular Malformations Diagnosis and Treatment
- French Language Learning Methods
- Hemodynamic Monitoring and Therapy
Laboratoire de Neurosciences Cognitives
2011-2025
Idorsia (Switzerland)
2019-2024
Aix-Marseille Université
2011-2023
Centre National de la Recherche Scientifique
2021-2022
Laboratoire Cognitions Humaine et Artificielle
2009-2019
Université Paris-Est Créteil
2018-2019
Laboratoire d’Ingénierie des Systèmes Physiques et Numériques
2017-2018
Cité des Sciences et de l'Industrie
2018
Actelion (Switzerland)
2005-2017
Académie de Paris
2016
In a phase 2 trial, selexipag, an oral selective IP prostacyclin-receptor agonist, was shown to be beneficial in the treatment of pulmonary arterial hypertension.In this event-driven, 3, randomized, double-blind, placebo-controlled we randomly assigned 1156 patients with hypertension receive placebo or selexipag individualized doses (maximum dose, 1600 μg twice daily). Patients were eligible for enrollment if they not receiving stable dose endothelin-receptor antagonist, phosphodiesterase...
Background and Purpose— This randomized, double-blind, placebo-controlled, dose-finding study assessed efficacy safety of 1, 5, 15 mg/h intravenous clazosentan, an endothelin receptor antagonist, in preventing vasospasm after aneurysmal subarachnoid hemorrhage. Methods— Patients (n=413) were randomized to placebo or clazosentan beginning within 56 hours continued up 14 days initiation treatment. The primary end point was moderate severe angiographic based on centrally read, blinded...
Plasma concentrations of the vasoconstrictor peptide endothelin-1 are increased in patients with heart failure, and higher associated worse outcomes. Tezosentan is an intravenous short-acting endothelin receptor antagonist that has favorable hemodynamic actions failure.To determine if tezosentan improves outcomes acute failure.The Value Endothelin Receptor Inhibition With Acute Heart Failure Studies, 2 independent, identical, concurrent randomized, double-blind, placebo-controlled,...
Clazosentan, an endothelin receptor antagonist, has been shown to reduce vasospasm after aneurysmal subarachnoid hemorrhage (aSAH). CONSCIOUS-3 assessed whether clazosentan reduced vasospasm-related morbidity and all-cause mortality postaSAH secured by endovascular coiling.This double-blind, placebo-controlled, phase III trial randomized patients with aSAH coiling ≤ 14 days intravenous (5 or 15 mg/h) placebo. The primary composite end point (all-cause mortality; new cerebral infarcts delayed...
<i>Objectives:</i> Recent heart failure studies have suggested that inflammatory and immune system activation are associated with increased levels of cytokines, chemokines proteins during acutely decompensated failure. The objectives this substudy were to evaluate the role neurohormonal in pathogenesis outcome acute (AHF) correlation between biomarker clinical outcomes. <i>Methods:</i> Serum B-type natriuretic peptide-32 (BNP-32), endothelin-1 (ET-1), norepinephrine,...
Objective To determine the effect of selexipag, an oral, selective IP prostacyclin receptor agonist, on frequency attacks Raynaud's phenomenon ( RP ) in patients with systemic sclerosis SS c). Methods Patients c‐related were randomized 1:1 to placebo (n = 38) or selexipag 36) individualized doses (maximum 1,600 μg twice daily) during a 3‐week titration period. The primary end point was weekly average number study maintenance period, analyzed using Bayesian approach negative binomial model...
Reading on a web page is known to be not linear and people need make fast decisions about whether they have stop or reading. In such context, reading, decision-making processes are intertwined this experiment attempts separate them through electrophysiological patterns provided by the Eye-Fixation-Related Potentials technique (EFRPs). We conducted an in which EFRPs were recorded while participants read blocks of text that semantically highly related, moderately unrelated given goal....
Previous results showed a positive influence of music training on linguistic abilities at both attentive and preattentive levels. Here, we investigate whether six months active is more efficient than painting to improve the processing phonological parameters based durations that are often impaired in children with developmental dyslexia (DD). Results were also compared control group Typically Developing (TD) matched reading age. We used Test-Training-Retest procedure analysed Mismatch...
Many lines of evidence have revealed limitations the human visual system, most notably that only a portion available information is processed in single glance. A degree conceptual confusion has emerged, however, regarding underlying concepts or mechanisms explaining limited processing reading; perceptual span, attention span. While original definitions these three are clear and well-differentiated, they routinely used inconsistently literature. The primary goal present review to re-specify...
The use of available treatments for Fabry disease (FD) (including enzyme replacement therapy [ERT]) may be restricted by their limited symptom improvement and mode administration. Lucerastat is currently being investigated in the MODIFY study as oral substrate reduction treatment FD. By reducing net globotriaosylceramide (Gb3) load tissues, lucerastat has disease-modifying potential to improve symptoms delay progression. a multicenter, double-blind, randomized, placebo-controlled,...
Fabry disease is an X-linked lysosomal storage disorder caused by a deficiency of α-galactosidase A. Symptoms include neuropathic pain and gastrointestinal problems, such as diarrhoea. To inform support the design Phase III clinical trial for new oral treatment disease, this study evaluated patients' experiences symptoms, impact symptoms on their quality life, views participating in trials.An online survey questionnaire was distributed to patients with through relevant patient organisations....
Three multidimensional scaling studies were conducted to compare the taste qualities evoked from electrical and chemical stimulation, including ferrous sulfate as a typical "metallic" stimulus. Bipolar, anodal, cathodal stimulation delivered by 1.5- or 3-V batteries applied tongue. Solutions of stimuli prototypical tastes binary mixtures evaporated on small metal disks provide tactile impressions similar those battery avoid any potential response biases induced subjects' knowledge form...